Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1NIH 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Head & Neck 1Gynecologic 1Gastrointestinal 1Breast 1

Conditions

Neoplasm Metastasis 7Stomach Neoplasms 2Breast Neoplasms 2Triple Negative Breast Neoplasms 1Salivary Gland Neoplasms 1Pancreatic Neoplasms 1Osteosarcoma 1Lung Neoplasms 1Endometrial Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinosarcoma 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Cetuximab 7Magnetic Resonance Spectroscopy 5Radiotherapy 4Erlotinib Hydrochloride 4Cisplatin 4Bevacizumab 4Trastuzumab 3Specimen Handling 3Radiotherapy, Conformal 3Carboplatin 3sargramostim 2ixabepilone 2Vorinostat 2Sorafenib 2SS1(dsFv)PE38 2Radiotherapy, Intensity-Modulated 2Radiosurgery 2Paclitaxel 2N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl-6-(5-((methylsulfonyl)ethyl)aminomethyl)-2-furyl)-4-quinazolinamine 2Lapatinib 2Fluorouracil 2Fluorodeoxyglucose F18 2Docetaxel 2Dasatinib 2Chemotherapy, Adjuvant 2Biopsy 2trastuzumab deruxtecan 1tipifarnib 1temsirolimus 1temoporfin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Salivary Gland Neoplasms × trastuzumab deruxtecan × Clear all
NCT04704661 2026-05-13

Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial

National Cancer Institute (NCI)

Phase 1 Active not recruiting
51 enrolled
BreastGastrointestinalGynecologicHead & NeckSarcoma

Breast Neoplasms, Carcinosarcoma, Colonic Neoplasms, Neoplasm Metastasis, Salivary Gland Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡